retatrutide and heart Data: What Surprised Cardiologists Dramatic Weight Loss, Cardiometabolic Improvement

The goal of GLP-1 therapy should be to lose fat and keep muscle not just to lose weight

Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients

Heres what early studies have shown: Pancreatitis: Reported in about 0.4% Gallbladder problems: Seen in about 1.1% , with no cases in the placebo group Heart rhythm changes: Reported more often with retatrutide ( about 6% vs 3% with placebo ) Liver enzyme increases: Rare (around 1% ), with overall liver health markers staying stable While these serious side effects were uncommon, theyre still important to keep in mind

The key takeaway is documentation

With semaglutide's patent expiring in 2031 and political pressure already forcing price cuts, GLP-1s are on a much faster timeline than insulin was

Under normal conditions, the increase in E